- Home
- PHIO vs HOOK Comparison
PHIO vs HOOK Comparison
Compare PHIO & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- HOOK
- Stock Information
- Founded
- PHIO 2011
- HOOK 2011
- Country
- PHIO United States
- HOOK United States
- Employees
- PHIO N/A
- HOOK N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- PHIO Health Care
- HOOK Health Care
- Exchange
- PHIO Nasdaq
- HOOK Nasdaq
- Market Cap
- PHIO 8.6M
- HOOK 9.3M
- IPO Year
- PHIO N/A
- HOOK 2019
- Fundamental
- Price
- PHIO $2.00
- HOOK $1.59
- Analyst Decision
- PHIO Strong Buy
- HOOK Buy
- Analyst Count
- PHIO 1
- HOOK 4
- Target Price
- PHIO $4.00
- HOOK $10.67
- AVG Volume (30 Days)
- PHIO 875.3K
- HOOK 205.3K
- Earning Date
- PHIO 05-15-2025
- HOOK 05-15-2025
- Dividend Yield
- PHIO N/A
- HOOK N/A
- EPS Growth
- PHIO N/A
- HOOK N/A
- EPS
- PHIO N/A
- HOOK N/A
- Revenue
- PHIO N/A
- HOOK $9,351,000.00
- Revenue This Year
- PHIO N/A
- HOOK N/A
- Revenue Next Year
- PHIO N/A
- HOOK N/A
- P/E Ratio
- PHIO N/A
- HOOK N/A
- Revenue Growth
- PHIO N/A
- HOOK N/A
- 52 Week Low
- PHIO $0.97
- HOOK $0.72
- 52 Week High
- PHIO $9.79
- HOOK $9.09
- Technical
- Relative Strength Index (RSI)
- PHIO 54.98
- HOOK 59.36
- Support Level
- PHIO $1.71
- HOOK $1.45
- Resistance Level
- PHIO $2.08
- HOOK $1.62
- Average True Range (ATR)
- PHIO 0.13
- HOOK 0.16
- MACD
- PHIO 0.01
- HOOK -0.00
- Stochastic Oscillator
- PHIO 76.32
- HOOK 67.57
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.